{"prompt": "['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', \"New information suggests taking part in the study may not be in the participant's best\", 'interest.', 'If the subject withdraws consent for disclosure of future information, the Sponsor may retain and', 'continue to use any data collected before such a withdrawal of consent.', 'If a subject withdraws from the study, he/she may request destruction of any samples taken and', 'not tested, and the Investigator must document this in the study center study records.', 'See Schedule of Activities (Section 1.3) for data to be collected at the time of study', 'discontinuation and follow-up and for any further evaluations that need to be completed.', 'Subjects withdrawing from the study prematurely for reasons other than a study drug related AE', 'may be replaced at the discretion of the Investigator and Sponsor to ensure the required number', 'of evaluable subjects.', '7.3', 'Lost to Follow-up', 'A subject will be considered lost to follow-up if he or she repeatedly fails to return for scheduled', 'visits and is unable to be contacted by the study center.', 'The following actions must be taken if a subject fails to return to the clinic for a required study', 'visit:', 'The study center must attempt to contact the subject and reschedule the missed visit as soon', 'as possible and counsel the subject on the importance of maintaining the assigned visit', 'schedule and ascertain whether or not the subject wishes to and/or should continue in the', 'study.', 'Before a subject is deemed lost to follow-up, the Investigator or designee must make every', 'effort to regain contact with the subject (where possible, 3 telephone calls and, if necessary, a', \"certified letter to the subject's last known mailing address or local equivalent methods).\", \"These contact attempts should be documented in the subject's medical record.\", 'Should the subject continue to be unreachable, he/she will be considered to have withdrawn', 'from the study.', '29 October 2019', '37']['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', '8.0 STUDY ASSESSMENTS AND PROCEDURES', 'Study procedures and their timing are summarized in Section 1.3.', 'Protocol waivers or exemptions are not allowed.', 'Immediate safety concerns should be discussed with the Medical Monitor and the Sponsor or', 'designee immediately upon occurrence or awareness to determine if the subject should', 'continue or discontinue in the study.', 'Adherence to the study design requirements, including those specified in the Schedule of', 'Activities (see Section 1.3), is essential and required for study conduct.', 'All screening evaluations must be completed and reviewed to confirm that potential subjects', 'meet all eligibility criteria. The Investigator will maintain a screening log to record details of', 'all subjects screened and to confirm eligibility or record reasons for screening failure, as', 'applicable.', \"Procedures conducted as part of the subject's routine clinical management (eg, blood count)\", 'and obtained before signing of the ICF may be utilized for screening or baseline purposes', 'provided the procedures met the protocol specified criteria and were performed within the', 'time frame defined in the Schedule of Activities (see Section 1.3).', 'The maximum amount of blood collected from each subject over the duration of the study,', 'including any extra assessments that may be required, will not exceed 204 mL. Repeat or', 'unscheduled samples may be taken for safety reasons or for technical issues with the', 'samples.', '8.1', 'Efficacy Assessments', 'It is recommended that the same Investigator/Sub-Investigator complete the scales and', 'questionnaires at all time points for a given subject.', '8.1.1', 'Clinical Global Impression', 'The CGI scale will be used to assess the clinical response to study treatment. The change will be', 'categorized as \"Very much improved,\" \"Much improved,\\' \"Minimally improved,\" \"No change,\"', 'and \"Worsened\" according to the modified JDA severity index total score (see Appendix 8).', '8.1.2', 'Modified Japanese Dermatology Association (JDA) Severity Index', 'The modified JDA severity index score will be used for the assessment of the skin lesions,', 'assessment of systemic manifestations and laboratory findings, and change in affected BSA of', 'erythema, pustules, and edema (see Appendix 9).', 'The total severity score is categorized as Mild (total score: 1 to 6), Moderate (total score: 7 to', '10), or Severe (total score: 11 to 17).', '29 October 2019', '38']['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', '8.1.3', 'Psoriasis Area Severity Index (Only in Subjects With PP)', 'Psoriasis Area Severity Index scores will be used to determine the treatment response in subjects', 'with PP. The PASI total score includes plaque characteristics (ie, erythema, induration, scaling),', 'percentage of BSA affected and should be calculated by electronic data capture (EDC) (see', 'Appendix 10).', '8.1.4', \"Generalized Pustular Psoriasis Physician's Global Assessment Scale\", 'The GPPPGA is a physician-based assessment of the severity of GPP (specifically pustules,', 'erythema, and scaling or crusting of pustular psoriasis lesions). Each component is scored on a 5-', 'point scale, ranging from 0 (least severe) to 4 (most severe) to assess the severity of GPP', '(Bachelez 2019; Marrakchi 2019). The average is calculated for scoring.', 'Subjects will be assessed using the GPPPGA at each study visit (excluding those visits that are', 'phone calls). Refer to Appendix 11 for additional information.', '8.1.5', 'Dermatology Life Quality Index', \"The DLQI Questionnaire will be used to assess treatment response on the subject's QoL. The\", \"aim of this questionnaire is to measure how much the skin condition has affected subject's life\", 'during the previous week.', 'Subjects will be asked to recall their experiences during the previous week by responding to', '10 questions. The DLQI will be completed by the subject on a worksheet prior to any safety or', 'efficacy evaluations. The questionnaire is self-explanatory and handed to the subject who is', 'asked to fill it in without the need for a detailed explanation (see Appendix 12).', '8.2', 'Safety Assessments', 'Planned time points for all safety assessments are provided in the Schedule of Activities (see', 'Section 1.3).', '8.2.1', 'Physical Examinations', 'Complete physical examinations will be performed at the time points indicated in the Schedule', 'of Activities (see Section 1.3).', 'A complete physical examination will include assessments of general appearance; skin;', 'head/neck; pulmonary, cardiovascular, gastrointestinal, external genitourinary, lymphatic,', 'and musculoskeletal system; extremities; eyes (inspection and vision control); nose; throat;', 'and neurologic status.', 'A detailed examination of the skin should be performed at the time points indicated in the', 'Schedule of Activities for the efficacy assessments (eg, CGI, modified JDA severity index,', 'PASI [if PP is present]).', 'Investigators should pay special attention to clinical signs related to previous serious illnesses.', '29 October 2019', '39']\n\n###\n\n", "completion": "END"}